Mar 5 |
Immutep Announces First Clinical Data from 90mg Dosing of Efti
|
Feb 29 |
Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%
|
Feb 5 |
10 Best Australian Stocks To Buy
|
Jan 30 |
Immutep Quarterly Activities Report Q2 FY24
|
Jan 4 |
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
|
Jan 3 |
Immutep: Upcoming Signals For 2024 (Maintain Buy)
|
Dec 21 |
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
Dec 7 |
Immutep receives A$2.6M R&D tax incentive from French Government
|
Dec 7 |
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
|
Nov 27 |
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
|